Chris Ogden
Förmögenhet: 461 070 $ per 2026-05-31
Förmögenhet: 461 070 $ per 2026-05-31
Chris Ogden is currently Chief Financial Officer, Secretary & Senior VP at CytomX Therapeutics, Inc. since 2021.
Former roles include Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Education includes an undergraduate degree from Wabash College and an MBA from Harvard Business School.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-06-15 | 128 075 ( 0,06 % ) | 461 070 $ | 2026-05-31 |
| Företag | Position | Start |
|---|---|---|
| CYTOMX THERAPEUTICS, INC. | Finansdirektör/CFO | 2022-09-21 |
| Företag | Position | Slut |
|---|---|---|
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Finansdirektör/CFO | - |
| ELI LILLY AND COMPANY | Företagsledare/Principal | - |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 5 |
|---|---|
Eli Lilly & Co.
Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
Wabash College
Wabash College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly del Caribe, Inc.
Lilly del Caribe, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceuticals | Health Technology |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån